Extra time, frequent breaks, standing desks and quieter workspaces are common adjustments for children with ADHD, but a US trial published in JAMA Pediatrics on 13 November found none of them improved the children’s behaviour or schoolwork, while behaviour therapy and stimulant medication both did.
Researchers led by Gregory Fabiano at Florida International University enrolled 280 children aged five to 12 with ADHD in a summer treatment programme, and 255 started the trial. Over several weeks the children rotated between days with and without accommodations, weeks on a low dose of methylphenidate or a placebo, and classrooms with and without an enhanced behaviour programme.
Medication lifted the amount of seatwork the children finished by 22% and raised their quiz scores, and it cut rule-breaking by 37%. The behaviour programme cut rule-breaking by 61%. The authors found no evidence that any of the academic accommodations significantly improved behaviour or results.
What NZ experts say
University of Auckland developmental neuropsychology professor Karen Waldie says the findings came as no surprise. She said people with ADHD tend to work well under pressure, with hard deadlines and quick consequences, and less well when they have plenty of time for a task.
Melanie Woodfield, a clinical psychologist and honorary senior lecturer at the University of Auckland, said the trial favoured strict control over real-world conditions, in a specialist US summer classroom where staff even tracked the ratio of praise to commands.
“This study is an important ‘signal’, from a carefully designed experiment, but it needs testing in the real world,” she said. She added that some accommodations do work for some children some of the time.
Clinical psychologist Giselle Bahr of Te Aro Psychology said NZ classrooms have twice as many children and half as many teachers, so it’s unclear how far the results apply here. She noted the trial used 0.3mg of methylphenidate per kilogram of body weight, while the Best Practice Advocacy Centre (bpacnz) tells NZ prescribers a response is typically expected at 0.5 to 1mg/kg. Bahr said NZ prescribing patterns may benefit from review.
How NZ schools handle ADHD
In NCEA exams, NZQA doesn’t treat ADHD as a category of its own for special assessment conditions. Its guidance lists rest breaks, a separate room and permission to take medication as the conditions available for ADHD, while extra time is listed for conditions such as dyslexia.
NZQA told an Official Information Act requester in January that applications citing ADHD and no other listed condition rose from 216 in 2018 to 1,878 in 2025, and it approved 1,874 of last year’s.
Since 1 February 2026, GPs and nurse practitioners can start stimulant treatment for adults aged 18 and over, under a Pharmac decision from June 2025, but treatment for under-18s still has to begin with a specialist or a nurse practitioner in a child and youth service. Pharmac funded a new brand of extended-release methylphenidate from December 2025 after supply problems that have affected every form of the medicine in New Zealand since August 2023.
The US National Institutes of Health funded the trial, and Woodfield said the authors have recommended it be repeated in ordinary classrooms, where they expect the effects to be weaker.